Travis LeGuyader

Travis LeGuyader

Recent posts by Travis LeGuyader

2 min read

FREE WEBINAR: High Throughput Antibody Discovery Targeting Cell Surface Receptors for Signaling Blocking in Cancer

By Travis LeGuyader on 4/14/20 3:11 PM

On-cell receptor functionality is a crucial threshold for drug development. By leveraging high content screening in antibody discovery workflows, you are able to improve the likelihood of campaign success at early stages of development. Join us for our webinar hosted by our COO Tracey Mullen and our friends at Sartorius, where Tracey will walk through a case study outlining how we incorporate this technology for antibody discovery projects targeting cell surface receptors. 

Tuesday, April 28, 2020, 11 am EDT

View on-demand webinar

The use of monoclonal antibody-based therapeutics to target and treat cancer is considered to be one of the most successful therapeutic strategy within the oncology field to date. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution, early stage characterization of lead antibody drug candidates prior to preclinical development. In this webinar, Tracey Mullen, COO of Abveris, will review an antibody discovery campaign targeting a cell surface receptor implicated in cancer. Methods for immunization, antibody discovery, and subsequent functional characterization will be detailed.

Who Should Attend:
  • Antibody discovery scientists and researchers engaged in therapeutic drug discovery in oncology indications

  • Anyone interested in learning more about incorporating high-throughput flow cytometry analysis into early stage research and development

Tracey Mullen, Chief Operating Officer, Abveris

Tracey Mullen is a chemical-biological engineer from MIT who began her career as an Antibody Discovery Scientist at a startup contract research organization specializing in in vivo antibody discovery. In 2013, she joined the Antibody Discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to tough targets, including leveraging the Adimab platform to enerate antibodies against GPCRs. In June of 2018, Tracey joined Abveris Antibody as the Director of Antibody Discovery Operations, where she managed project design and development for in vivo discovery projects. She is now the Chief Operating Officer at AbX Biologics (formerly Abveris), a premium antibody discovery service partner boasting industry-leading timelines and cutting-edge technologies.

Carrie Haslam, Associate Editor, Select Science

Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Alzheimer’s disease and clinical diagnostics. She is finalizing her Ph.D. from Plymouth University, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.

View on-demand webinar

Topics: Insider Service & Product Updates Events
2 min read

Abveris and ACROBiosystems extend partnership

By Travis LeGuyader on 4/8/20 7:00 AM

Canton, MA, USA and Newark, DE, USA, April 8, 2020 - Abveris, Inc., a leader in contract research antibody discovery, today announced the extension of a strategic collaboration with ACROBiosystems, an internationally recognized manufacturer of recombinant proteins.

Under the terms of the agreement, the companies will leverage their core technologies to construct streamlined offerings to accelerate the pace of antibody discovery research.

Acro LogoBy the terms of the agreement, over 1600 recombinant proteins for biologic drug discovery and development available in the ACROBiosystems catalog will be made available to Abveris customers to facilitate rapid initiation of antibody discovery projects.

1600+ reagents at your fingertips click here to view the acro catalog

"Our collaboration with ACROBiosystems is a highly valuable resource for Abveris and all of our partner companies,” commented Ryan Kelly, Director of Business Development at Abveris. "Our access to ACRO’s high-quality “off-the-shelf” reagents allows us to identify diverse, high affinity antibody clones in as little as one month total.”

“We are delighted to collaborate with Abveris, who shows their expertise in therapeutic antibody development. Their special DiversimAbTM platform and single B cell screening platform speed up the antibody generation process while providing maximum diversity and affinity of the antibody candidates. It delivers additional benefits and comforts to scientists with using ACRO’s high-quality reagents and Abveris’s technologies as a combination,” commented Simin He, Marketing Manager of ACROBiosystems.


About Abveris: 

Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at

About ACROBiosystems: 

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. Check out more details at:

Contact for Abveris:

Ryan Kelly

Director of Business Development

781-562-1170 x1002

Contact for ACROBiosystems:

Grace Wang

Marketing Specialist



Topics: Insider Service & Product Updates
1 min read

Hey, Boston & Cambridge!  We're hosting a free happy hour!

By Travis LeGuyader on 2/12/20 7:30 AM

Updated 3/6/20: Event cancelled due to concerns surrounding spread of COVID-19 virus. 
A note from the event organizers:
Thank you for your interest in our event, and we apologize that we must postpone the happy hour indefinitely due to concerns surrounding the spread of Covid-19 infection. 
We're proud to announce that we had over 100 attendees registered a week ahead of the event. When the time is right, we will announce a revised event date. 

Thursday | March 12 | 5:00-7:30 PM | Cambridge, MA

Open Bar & Free Appetizers

What is Brews & Biopharma?

A free happy hour for biopharma scientists.

An exclusive, relaxed event for biopharma scientists in the protein sciences. Finish your workday (and start your night) with us over casual drinks, appetizers, and networking.

Who is invited?

Scientists from our partner companies and their invited guests*

*We kindly ask you not to invite your professional recruiter or salesperson friends as your guests. Nobody likes to be pitched after work. Thank you for respecting our policy. 

Topics: Insider Events
1 min read

COO of Abveris, Tracey Mullen, to Present at Antibody Engineering 2019 in San Diego

By Travis LeGuyader on 12/3/19 1:49 PM

December 9, 2019 – San Diego, CA - Are you attending the upcoming Antibody Engineering and Therapeutics conference in San Diego on December 9th? It’s not too late to sign up and spend some time in the sun while staying updated on the latest antibody discovery technologies and engineering techniques while networking with lead scientists in the antibody discovery world.

Join us on December 12 at noon for a scientific briefing led by Tracey Mullen, our Chief Operating Officer. Or, stop by our booth or posters in the exhibit hall and meet with Garren (CEO), Ryan (Director of Business Development) and Travis (Business Development Associate). See you there!

Click here to schedule an appointment with our team at the conference.


Information on our Scientific Briefing:
Scientific Briefing: Antibody Discovery for Traditionally Difficult Targets: in vivo, in vitro, or both?

Abstract: Leveraging the natural immune repertoire for antibody discovery has distinct advantages for positive downstream outcomes, including efficacy, developability and safety; however, traditional techniques typically fail to produce a productive response in situations where, for example, the target epitope has poor immunogenicity or is a rare, cryptic site. While some in vitro platforms can overcome these difficulties through careful guiding selection methods, significant downstream engineering is often required to ensure lead candidates harbor appropriate development qualities. Fortunately, recent advancements in protein engineering and antibody discovery have enabled improved drug development to these traditionally difficult targets. Using the AbX platform, the power of the immune system is harnessed to exemplify the breadth and comprehensive nature of the B cell repertoire. When applied to the most difficult target classes, lead candidates can be uncovered where traditional in vivo platforms typically fail, or significant engineering is required for in vitro discovery.

About the Antibody Engineering Conference: Antibody Engineering is the #1 antibody engineering conference for accelerating next-generation antibodies to commercial success. Find the latest science, technology, and partners in antibody engineering, immunobiology, and next-generation binders.


Antibody Engineering Logo


Topics: Conferences
1 min read

WEBINAR: Excellence In Anti-Idiotype Antibody Discovery

By Travis LeGuyader on 10/28/19 6:29 PM

Date: November 13, 2019 at 2PM ET (11AM PT)
TraceyMullenPlease join Abveris' Chief Operating Officer, Tracey Mullen, for our webinar to learn more about our premier anti-idiotype antibody discovery service for mAbs, bispecifics, scFvs, VHHs, and more.

Benefits of our approach:
  • Rapid reagent generation timelines
  • Maximal epitope coverage with DiversimAb technology
  • Highly sensitive specificity screening
  • Identification of high-affinity mAbs
  • Neutralizing and non-neutralizing mAbs
  • Flexible deliverable strategies
  • All work done in the USA

Abveris has the expertise and technology advantages required to develop high-quality reagents to the trickiest biotherapeutic molecules. Join our webinar to learn more.
Interested, but have a scheduling conflict? Click here to register, and a video link will be sent after the webinar finishes. 
Topics: Insider Service & Product Updates
1 min read

Abveris and Geneious Biologics Collaborate to Advance Antibody NGS Data Analysis

By Travis LeGuyader on 8/12/19 8:01 AM

Canton, MA, USA – August 12, 2019 – Boston-based antibody discovery services company Abveris has partnered with Biomatters to incorporate the Geneious Biologics data analysis platform into their antibody discovery workflow. In collaboration, a new Single Clone Antibody Annotator pipeline has been developed.

With a rapidly growing customer base and a wide range of antibody discovery services, Abveris plans to leverage the Geneious Biologics platform as a premium hub for bioinformatics and computer programming capabilities.

"The Geneious team has done an excellent job accommodating our specific data resulting in a streamlined, high-throughput workflow that produces accurate data and operates efficiently without the need to integrate multiple bioinformatics platforms," remarked Dr. Colby Souders, Chief Technology Officer at Abveris. "We look forward to continuously improving the platform and its integration into our workflow to combine sequence analytics with metadata and assay data to accelerate candidate selection."

The Geneious team worked closely with Abveris to optimize and enhance the handling of their antibody NGS data. Jannick Bendtsen, VP Technology Services at Geneious, commented, "Abveris is at the cutting edge of antibody drug discovery; they are pushing the boundaries of science and technology. To have Colby and the team select Geneious Biologics is a great honor and a great compliment. We collaborated to integrate our Single Clone Antibody Annotator Pipeline, and it now runs out of the box. It's all about speed and accuracy in the discovery process."

About Abveris: Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at

About Geneious and Biomatters: Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights across the spectrum of biotechnology research and development, including drug discovery, protein engineering, and advanced comparative analysis of DNA, RNA, and protein sequences. Geneious solutions are created from a deep understanding of customer experience to turn the difficult into the intuitive and easy. Geneious is trusted by over 4,000 companies, universities, and institutes all over the globe. Additional information about Geneious is available at

Topics: Press Releases Service & Product Updates